Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option

FDA's June 30 approval of Genentech's Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration includes the possibility for less frequent, quarterly dosing